History
Main Menu
Menu
2025
REGENECYTE received the 2025 Outstanding Biotech Industry Award – Industry Innovation of the Year.
Phase I clinical trial results of cord blood therapy for acute ischemic stroke were published in the Tzu Chi Medical Journal.
2024
Received U.S. FDA and Taiwan TFDA approval for a Phase II clinical trial of cord blood therapy for acute ischemic stroke.
Received Taiwan TFDA approval for a Phase I clinical trial of cord blood therapy for cerebral palsy.
REGENECYTE received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.
Announced Phase II clinical trial results for REGENECYTE in the treatment of long COVID, with 85% of patients achieving complete resolution of fatigue after treatment and meeting the efficacy endpoint.
REGENECYTE received U.S. FDA approval through a Biologics License Application (BLA).
2023
Received U.S. FDA approval to initiate a Phase II clinical trial of REGENECYTE for the treatment of long COVID and began patient enrollment.
Completed all patient follow-up visits for a TFDA-approved Phase I clinical trial of cord blood therapy for acute ischemic stroke.
Published a case report in the prestigious international journal Cell on the use of REGENECYTE in combination with peripheral blood stem cells to treat HIV and acute leukemia.
Collaborated with Taichung Veterans General Hospital to complete a clinical case using sibling-derived mesenchymal stem cells to treat hypoxic-ischemic brain injury.
2022
Submitted a Biologics License Application (BLA) to the U.S. FDA for REGENECYTE, a cord blood product for the treatment of hematologic diseases.
Collaborated with Taipei Medical University to complete the world’s first clinical case involving the administration of three cord blood units to an adult patient with cerebral palsy.
2021
Approval by Taiwan FDA to conduct Phase 2 multi-center clinical trial in multiple countries for the use of MC001, a new drug using umbilical cord blood mononuclear cells for the treatment of spinal cord injury (USA/Taiwan).
2019
Approval by Taiwan FDA for Taiwan Cord Blood Corporation and Tzu Chi Hospital to collaborate on conducting Phase 1 clinical trial for the treatment of acute ischemic stroke using umbilical cord blood stem cells (Taiwan).
2016
Published Phase I/II clinical trial results of MC001 for chronic spinal cord injury in the international medical journal Cell Transplantation.
2015
Assisted in the successful transplantation of 2,000 cases using umbilical cord blood.
2014
Approval by Taiwan FDA to conduct Phase 1 clinical trial for the treatment of acute ischemic stroke using umbilical cord blood stem cells (Taiwan).
2013
Completion of Phase 1/2 clinical trial for MC001, a new drug using umbilical cord blood mononuclear cells for the treatment of spinal cord injury (Hong Kong/China).
2012
StemCyte Inc. US partnered with UC Davis to execute the California Umbilical Cord Blood Collection Program
2010
The Phase 1/2 clinical trial of the cord blood mononuclear cell therapy MC001 for spinal cord injury included the first subject in Hong Kong.
2009
StemCyte India was founded in India
2007
Eternal Life USA Becomes the World’s First Private Cord Blood Bank Certified by FACT (Foundation for the Accreditation of Cell Therapy) to Offer Both Private Storage and Public Donation
Eternal Life USA Becomes the First Private Cord Blood Bank to Partner with the U.S. Government (HRSA)
2006
StemCyte, Inc. received FACT accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT).
StemCyte, Inc. was commissioned by the U.S. Health Resources and Services Administration (HRSA) to support the National Cord Blood Inventory (NCBI) collection program.
2005
StemCyte Taiwan became the only foreign member to receive the NMDP (National Marrow Donor Program) Special Project Award globally
2004
StemCyte Taiwan received AABB accreditation for cord blood banking
2003
StemCyte Inc. US received AABB (American Association of Blood Banks) accreditation for cord blood banking
2002
StemCyte Taiwan was founded in Taiwan
2001
Began collecting publicly donated cord blood in Taiwan.
2000
Began collecting and providing cord blood for transplantation in California, USA.
StemCyte Taiwan was established.
1998
Developed cord blood storage technologies and established standard operating procedures (SOPs) for cord blood banking.
1997